Nucleix Presents Two Bladder EpiCheck® Studies at EAU20 Virtual Congress, Including Interim Data in Patients with Upper Tract Urothelial Cancer

SAN DIEGO & REHOVOT, Israel- Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced two presentations featuring its Bladder EpiCheck® technology at the 35th Annual European Association of Urology (EAU) Virtual Congress.

SOCIAL MEDIA

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the
email and you’re good to go.

GOT IT !